MIRM Live signals | Maximize Profits with Getagraph.com

SELL 99036 min ago

@ $28.45

Issued: 14 Feb 2024 @ 09:30

Return: -15.04%

Previous signal: Feb 13 - 12:55

Previous signal: Buy

Return: -0.45 %

Live Chart Being Loaded With Signals

Commentary (22 Apr 2024 @ 16:00):

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases...

Stats
Today's Volume	250 182
Average Volume	505 527
Market Cap	1.13B
EPS	$0 ( 2024-02-28 )
Next earnings date	( $-0.370 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.04
ATR14	$0.0230 (0.10%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-27	Bjerkholt Eric	Buy	2 000	Common Stock
2024-03-25	Radovich Peter	Sell	4 303	Common Stock
2023-01-09	Radovich Peter	Sell	1 379	Common Stock
2023-01-09	Vig Pamela	Sell	1 379	Common Stock
2019-09-10	Longpre Lara	Buy	965	Common Stock

INSIDER POWER
-83.28
Last 98 transactions
Buy: 1 143 723 \| Sell: 16 296 571

Volume Correlation

Long: -0.32 (neutral)

Short: 0.68 (moderate)

Signal:(51.544) Neutral

Mirum Pharmaceuticals Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Mirum Pharmaceuticals Inc Correlation - Currency/Commodity

0.05
( neutral )

0.62
( weak )

0.00
( neutral )

-0.55
( weak negative )

-0.06
( neutral )

0.41
( neutral )

Mirum Pharmaceuticals Inc Financials

Annual	2023
Revenue:	$186.37M
Gross Profit:	$139.01M (74.58 %)
EPS:	$-4.00

Q4	2023
Revenue:	$69.55M
Gross Profit:	$46.95M (67.50 %)
EPS:	$-0.710

Q3	2023
Revenue:	$47.73M
Gross Profit:	$37.50M (78.57 %)
EPS:	$-0.570

Q2	2023
Revenue:	$37.50M
Gross Profit:	$30.69M (81.83 %)
EPS:	$-1.940

Financial Reports:

No articles found.

Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.